Group 1 - The core viewpoint of the event emphasizes the significant market growth potential of new therapies such as cell and gene therapy, bispecific antibodies, and antibody-drug conjugates (ADCs), alongside the rapid development of artificial intelligence providing more possibilities for disease treatment [1] - The Chinese innovative drug industry has been accelerating its international expansion, with a notable increase in the accessibility of innovative biopharmaceuticals over the past decade [1] - The establishment of a standardized clinical-grade stem cell resource bank is identified as a core support for the sustainable development of the industry, necessitating simultaneous advancements in technological innovation and ethical regulations [1] Group 2 - The roundtable discussion highlighted the shift in human health perspectives from "fighting diseases" to "controlling life quality," driven by breakthroughs in emerging biotechnologies [2] - The event aims to bridge the gap between academia and industry, fostering cross-disciplinary exchanges to explore new paradigms and pathways for technological innovation [2] - Future discussions will focus on cutting-edge technologies such as artificial intelligence, photonics, and synthetic biology, promoting the integration of future technologies with future industries [2]

Core Insights - The article discusses the increasing trend of licensing transactions between Chinese biotechnology companies and global pharmaceutical firms amid tense US-China trade relations, with expected growth in transaction volume and upfront payments [2][6]. Group 1: Licensing Activity Trends - A survey indicates that licensing transactions between Chinese enterprises and global pharmaceutical/biotech companies are on the rise, with a median expected transaction volume growth of 5% and a median upfront payment growth of 2.5% in 2024 [6]. - In 2024, it is projected that 43 transactions will be completed, with an average upfront payment of $92.5 million and an average total value of $1.4 billion [6]. Group 2: Preferred Drug Development Platforms - Antibody-drug conjugates (ADCs) remain the most favored drug development technology platform among global pharmaceutical and biotech companies, with 36% of respondents selecting it as their top choice [12]. - Gene therapy ranks second in attractiveness at 16%, followed by bispecific antibodies and T-cell engagers at 15% [12]. - Cell therapies, including CAR-T and CAR-NK, have the lowest appeal at 1%, potentially influenced by the uneven distribution of Chinese enterprises across various treatment fields [12].